The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ICML 2019 | Autologous or allogeneic stem cell transplant for consolidation therapy in T-cell lymphomas?

Jun 26, 2019

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Olivier Tournilhac from Clermont-Ferrand University Hospital, Clermont-Ferrand, FR, about whether autologous or allogeneic stem cell transplant should be used as consolidation for T-cell lymphomas.

Olivier Tournilhac discussed the multicenter AATT trial, which addressed the first-line treatment of peripheral T-cell lymphoma. Over the period of 3 years, 104 patients were enrolled, with the main aim to improve event-free survival by 25%, with final results showing no improvement using allogeneic transplantation compared with autologous transplantation.

Autologous or allogeneic stem cell transplant for consolidation therapy in T-cell lymphomas?